IBSA on the front line against pharmaceutical counterfeiting30 June 2019
IBSA IS ON THE FRONT LINE AGAINST ONE OF THE WORST SCOURGES IN THE PHARMACEUTICAL MARKET, ESPECIALLY IN EMERGING AND DEVELOPING COUNTRIES: COUNTERFEITING.
To combat this scourge, which harms people and patients, as well as damaging companies, IBSA has chosen, for its products, primary and secondary packaging materials provided with Tamper Evident systems and has implemented a traceability project involving the application of a barcode and a 2D reading system on an innovative adhesive label so that the data cannot be modified or altered. The company has achieved total traceability of the product life cycle thanks to the collaboration and strong support to the project of its business partners. Literally: from the manufacturer to the end user, with no possibility of error or deviation.
Launched with a pilot project inspired by the European Directive against Counterfeiting, IBSA's new packaging traceability system had an incubation period of over 3 months between development and testing, before being activated. Today, one year after its launch, IBSA can announce that it has succeeded: thanks to the new electronic management system for products, it has identified a number of unethical distributors and their accomplices in the black market and counterfeiting and reported them to the competent authorities. In particular, IBSA’s focus has been on protecting an important medical device heavily attacked by unauthorised distributors and plans to apply it to Sildenafil, a drug that is heavily targeted by counterfeiters. Thanks to the traceability system and Tamper Evident systems applied to packages, IBSA can now trace every single product batch and guarantee its authenticity, safety and legal origin.
For a company dedicated to the health and care of people, the CEO of IBSA Italy, Luca Crippa, stated “this is a just battle, which we will fight to the end alongside our colleagues and especially all patients who look to us with confidence and hope. It's a question of work ethics, not just business ethics.”